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Background: Beckwith-Wiedemann syndrome (BWS) is a rare pediatric overgrowth disorder with a variable
clinical phenotype caused by deregulation affecting imprinted genes in the chromosomal region 11p15. Alterations
of the imprinting control region 1 (ICR1) at the IGF2/H19 locus resulting in biallelic expression of IGF2 and
biallelic silencing of H19 account for approximately 10% of patients with BWS. The majority of these patients have
epimutations of the ICR1 without detectable DNA sequence changes. Only a few patients were found to have
deletions. Most of these deletions are small affecting different parts of the ICR1 differentially methylated region
(ICR1-DMR) removing target sequences for CTCF. Only a very few deletions reported so far include the H19 gene in
addition to the CTCF binding sites. None of these deletions include IGF2.
Case presentation: A male patient was born with hypotonia, facial dysmorphisms and hypoglycemia suggestive
of Beckwith-Wiedemann syndrome. Using methylation-specific (MS)-MLPA (Multiplex ligation-dependent probe
amplification) we have identified a maternally inherited large deletion of the ICR1 region in a patient and his mother.
The deletion results in a variable clinical expression with a classical BWS in the mother and a more severe presentation
of BWS in her son. By genome-wide SNP array analysis the deletion was found to span ~100 kb genomic DNA
including the ICR1DMR, H19, two adjacent non-imprinted genes and two of three predicted enhancer elements
downstream to H19. Methylation analysis by deep bisulfite next generation sequencing revealed hypermethylation
of the maternal allele at the IGF2 locus in both, mother and child, although IGF2 is not affected by the deletion.
Conclusions: We here report on a novel large familial deletion of the ICR1 region in a BWS family. Due to the
deletion of the ICR1-DMR CTCF binding cannot take place and the residual enhancer elements have access to the
IGF2 promoters. The aberrant methylation (hypermethylation) of the maternal IGF2 allele in both affected family
members may reflect the active state of the normally silenced maternal IGF2 copy and can be a consequence of
the deletion. The deletion results in a variable clinical phenotype and expression.
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Beckwith-Wiedemann syndrome (OMIM 130650) is an
overgrowth disorder characterized by exomphalos/om-
phalocele, macroglossia, gigantism and high risk for tumor
development [1-3]. BWS has an estimated pan-ethnic inci-
dence of 1/13,700. It is usually sporadically transmitted
(85%), but familial occurrence has been reported in about* Correspondence: efrysira@yahoo.gr
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unless otherwise stated.15% of cases [3]. Variations in clinical manifestations may
be linked to molecular heterogeneity [4]. Different and
complex molecular mechanisms have been implicated in
the dysregulation of imprinted growth regulatory genes on
chromosome 11p15 [5].
Evidence of three major or two major and three minor
criteria usually supports the diagnosis of BWS. Major
clinical findings includes among others: macrosomia,
macroglossia, omphalocele or umbilical hernia, ear pits
or anterior linear ear lobe creases, visceromegaly, adreno-
cortical cytomegaly, hemihyperplasia, renal abnormalities,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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neonatal hypoglycemia, characteristic facies, advanced
bone age, naevus flammeus, cleft palate, rectus diastesis
and cardiac anomalies [6].
Genomic imprinting is an epigenetic mechanism of gene
modification, starting during gametogenesis and resulting
in the differential expression of the paternal and maternal
alleles during development. By this process, genes which
are subject to genomic imprinting are expressed from one
parental allele only. Deregulation of imprinted genes
can lead to specific diseases. BWS syndrome is one of
the most well-known human diseases implicated in gen-
omic imprinting [7].
The 11p15.5 region contains two clusters of imprinted
genes, which play a role in cell cycle and growth regula-
tion [8,9]. Imprinted expression of these two gene clusters
are regulated by two independent imprinting control re-
gions, ICR1 and ICR2. ICR1 regulates the imprinted ex-
pression of genes in the most telomeric imprinted region
including the insulin like growth factor 2 (IGF2) and H19.
Molecular alterations affecting the ICR1 in patients with
BWS lead to biallelic expression of IGF2 and to loss of
function of H19. ICR2 controls the imprinted expression
of genes in the more centromeric region, such as cyclin-
dependent kinase inhibitor 1C (CDKN1C/p57), potassium
voltage-gated channel subfamily Q member 1 (KCNQ1)
and KCNQ1- overlapping transcript 1 (KCNQ1OT1 or
LIT1) [8,9]. Molecular alterations in BWS affecting the
ICR2 lead to silencing of CDKN1C and KCNQ1 and
biallelic expression of KCNQ1OT1. At least one of the
many genetic/epigenetic alterations is recognized in ~ 80%
of cases [9] and includes the following:
 Isolated hypomethylation of the KvDMR/ICR2
(~50-60%), which is implicated with the reduction
of CDKN1C/p57 expression
 Paternal uniparental isodisomy of 11p15.5 (~20%)
 Isolated gain of methylation of ICR1 and biallelic
IGF2 expression (2-7%)
 Chromosome rearrangements (dup(11)(p15) of
paternal origin) (1-2%)
 Maternal CDKN1C mutations, representing 5-10%
of sporadic cases and 4050% of familial cases
 Rare cases with maternal deletions affecting the
ICR1 or ICR2 (less than 1%)
 Rare cases with small deletions or mutations
affecting an OCT4 binding motif inside the
ICR1-DMR between H19 and IGF2.
Familial or de novo deletions in BWS affecting the ICR1
or ICR2 on chromosome 11p15 are rare findings. Only
four maternal deletions affecting the ICR2 have been re-
ported so far [10-13] However, in one case the deletion in-
cludes the CDKN1C gene, explaining the BWS phenotypebecause of the lack of the maternal CDKN1C transcript.
All these ICR2 deletions are large in size spanning 198-
900 kb genomic DNA. In contrast, most of the ICR1 dele-
tions identified so far, are small microdeletions of 0.5 to
2.8 kb affecting CTCF binding inside the ICR1 [14-21].
For some of these deletions (sized 1.4 kb, 1.8 kb and 2.2
kb, respectively) it has been shown that the phenotypical
outcome appears to depend on the spatial arrangement of
the remaining CTCF-binding sites [21]. Only a few larger
maternally inherited deletions in patients with BWS in-
cluding H19 in addition to the ICR1 have been described
recently by Baskin et al. [19] and one paternally inherited
deletion in a mosaic state, which interestingly lead to atyp-
ical Silver-Russel syndrome (SRS, an intrauterine growth
retardation syndrome) [22,23].
Here, we present a novel familial case of BWS, in
which the underlying molecular defect is a rare mater-
nally transmitted deletion of ~100 kb in size. The dele-
tion was found to be on the maternal chromosome 11
in the mother and her son. Both have BWS, although
the clinical phenotype of the son was more severe than
that of the mother. Hypermethylation of the DMR0 of
IGF2 in both affected family members, gives a hint for
biallelic expression of IGF2, which is causative for the
BWS phenotype.
Case presentation
The male patient of Greek origin was the only child of the
parents. He was born after 40 weeks of gestation through
a caesarian section due to breech presentation [birth
weight 3.250 (50th centile), length 53.5 cm (>95th centile),
head circumference 34.6 cm (50th centile)]. The Apgar
score was 8 at 1′ and 9 at 5′. The parents were non-
consanguineous (mother was 35 and father was 36 years
old) and the conception was not assisted. The pregnancy
and the prenatal ultrasound were reported as normal. The
mother of the child had macrosomia (height = 95th cen-
tile), large hands and feet with lymphedema of the lower
limbs. The mother’s phenotype from her childhood was
suggestive of the clinical diagnosis of BWS (gigantism,
macroglossia and small omphalocele). The patient’s father,
the maternal grandmother and grandfather were reported
as phenotypically normal.
At birth, the newborn was hypotonic with facial BWS
dysmorphisms, macrosomia but with no obvious om-
phalocele. There was a small palpable mass at the sacro-
coccygeal region (Figure 1A, B, C). In the first 24 hours,
the patient presented with hypoglycemia attributed to
hyperinsulinism and was treated with diazoxide. The
hypoglycemia was persistent and intractable. From the
biochemical screening, in addition to hypoglycemia, the
patient had AFP (60.500 ng/ml-normal range maximum
40.000), liver function tests (transaminases) and direct
bilirubin levels which were remarkably elevated, but with
Figure 1 Patient A. Pedigree of the BWS family. Deletion carriers are indicated by filled circles or boxes. B. Frontal view of the newborn patients
face C. Linear crease of the ear lobe D. Presence of omphalocele at 1 month.
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an atrial septal defect with mild hypertrophy of the
septum and the right ventricle, along with mild bilateral
stenosis of the pulmonary arteries. TORCH and meta-
bolic investigations were negative. Due to the intractable
hypoglycemia, a therapeutic trial with somatostatin was
also attempted, but without relevant clinical benefit. At
the age of two months, the proband was still mildly
hypotonic, had macrosomia, a notable umbilical hernia,
macroglossia, and hypertelorism with a flat nasal bridge,
all of which are clinical features of BWS. Heart ultra-
sound of the patient remained the same as during the
first 24 hours. Abdominal ultrasound and Magnetic Res-
onance Imaging (MRI) confirmed the hepatomegaly but
without dilatation of the intra and extrahepatic biliary
vessels, the splenomegaly, a normal pancreas, adrenals
and enlarged but otherwise morphologically normal kid-
neys. An X-ray of the left hand, also taken at two months,
revealed advanced bone age (one year more than hischronological age). Due to the presence of a small sacro-
coccygeal mass, MRI of the lower spine revealed spina
bifida at the level of I1-I2 vertebra. Because of the macro-
glossia, the patient developed severe upper airway conges-
tion and was placed on mechanical ventilation (CPAP).
After eight days his blood sugar stabilized. After 5 months
of hospitalization, his AFP levels dropped and he could
eat and breathe by himself. After clinical reevaluation at
the ages of 8, 12 and 15 months his macrosomia remained
out of the 97thcentile (above 2 SDs). At 15 months his de-
velopmental milestones were slightly delayed (he walks
with support) but he did not present a neurological deficit.
Cytogenetic analysis
Conventional karyotyping by G-banding technique was
carried out on stimulated peripheral blood cultures on
metaphase cells according to standard protocol. Fifty
metaphases with 550 band resolution (≥5 Mb) were
analyzed.
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Genomic DNA from peripheral blood was extracted ac-
cording to standard protocols (QIAGEN BioRobot M48,
MagAttract DNA Blood Kit, Hilden, Germany).
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA)
Gene dosage and methylation of the H19/ICR1-DMR/
IGF2 and ICR2 on chromosome 11p15 were analyzed by
MS-MLPA using the SALSA MLPA KIT ME030-C3
BWS/RSS (MRC Holland, Amsterdam, Netherlands).
Hybridization, ligation and PCR reactions were carried
out according to the manufacturer’s instructions. Amplifi-
cation products were analyzed by capillary electrophoresis
using the ABI3100 or 3500 capillary sequencer, respect-
ively. Data analysis was carried out using the Gene Marker
Software (Softgenetics, State College, PA, USA).
Bisulfite treatment of DNA
Bisulfite treatment of genomic DNA was carried out
using the EZ DNA MethylationGold Kit (Zymo Research
Europe, Freiburg, Germany) according to the manufac-
turer’s protocol.
Deep bisulfite sequencing
Generation of bisulfite amplicon libraries, sample prep-
aration and sequencing on the Roche 454 GS junior sys-
tem was carried out as previously described [21,24]. For
the IGF2 DMR0 following primers were used (product
size 349 bp; Tm = 62°C): IGF2-DMR0-Ftag 5′-CTTGC
TTCCTGGCACGAG-AGATTTTTTTGTTGGATAGG
TTGTT-3′, IGF2-DMR0-RM13 5′- CAGGAAACAGCT
ATGACTCTATTACACCCTAAACCCAAACTC -3′ (in
bold universal tags). For allele separation we used the
SNP rs3741210 (A/G). For data analysis, we used the
Python-based amplikyzer software developed in-house [25].
Molecular karyotyping
Array analysis was carried out using the genome-wide
high-resolution SNP array CytoScan HD (Affymetrix)
according to the manufacturer′s protocols (Affymetrix,
SantaClara, California, USA). Evaluation of the data was
performed using the Affymetrix Chromosome Analysis
Suite version 2.0.
In silico enhancer characterization
Candidate enhancer sequences of the IGF2/H19 genes
have been identified through bioinformatics analysis for
the presence of the following characteristics: 1) conserved
non coding regions of at least 100 bp (>70% identical be-
tween human and rodents); 2) enriched histone H3K27
acetylation and H3K4 monomethylation; 3) DNase hyper-
sensitive sites and transcription factor binding [26-28].Results
Cytogenetic analysis had revealed a normal karyotype in
both, the mother and the patient. Because of the clinical
diagnosis of BWS in the propositus and his mother, a
combined gene dosage and methylation analysis by MS-
MLPA for the chromosome 11p15 imprinted region was
performed in both. In addition, the father of the proposi-
tus and the maternal grandparents were investigated by
MS-MLPA. By this method, a deletion affecting all nine of
the ICR1-DMR and H19 specific MLPA probes was de-
tected in the patient and his mother. All four methylation-
specific MLPA probes for the H19/ICR1-DMR showed
complete methylation in both affected individuals An add-
itional excel file presents detailed MLPA findings (see
Additional file 1: Table S1). In contrast, all other studied
family members showed a normal MLPA pattern. The ab-
errant methylation pattern in both affected individuals in-
dicated that both have the deletion on their unmethylated,
i.e. maternal chromosome explaining the BWS phenotype.
None of the MLPA probes for IGF2 or the ICR2 showed a
reduction in the gene dosage, indicating that the deletion
is restricted to the ICR1-DMR, H19 and probably to the
downstream region of H19. Since the maternal grand-
mother has no deletion (data not shown), the deletion in
the mother seems to be a de novo event; although a germ-
line mosaicism for a deletion in the grandmother cannot
be excluded.
To further narrow down the breakpoints of the identified
deletion in 11p, we performed genome wide array analysis
in the patient. By this approach we determined the size of
the deletion to at least 99.78 kb and at most 100.02 kb. The
deletion was described as arr[hg19] 11p15.5 (1,965, 037×2,
1,965, 0472, 064, 827×1, 2,065, 052×2). The deletion en-
compasses the H19, miR-675, the ICR1DMR and the adja-
cent non-imprinted genes MRPL23, MRPL23-AS1, but not
IGF2 or the ICR2 region (Figure 2). The centromeric break-
point is estimated to map ~52 kb downstream of H19. The
telomeric breakpoint maps approximately 46 kb upstream
of H19 and therefore 90 kb downstream of IGF2.
Mouse transgenic studies have identified multiple shared
enhancers for Igf2 and H19 between 10 and 120 kb 3′ of
H19 [29]. Enhancer sequences are characterized by con-
served non coding regions that are enriched in specific
histone modifications (i.e. H3K27acetylation, H3K4mono-
methylation), DNase hypersensitive sites and transcription
factor binding [28,30]. We identified four sequences meet-
ing these features at the IGF2/H19 locus (Figure 2). Three
of them are located 85, 26 and 10 kb at the 3′ of H19, re-
spectively, reflecting the position of murine enhancers that
have been identified by transgenic mouse studies [29]. A
fourth region with enhancer features is located in the
intergenic region between IGF2 and H19, at ~100 kb far
from H19. Two of these sequences are located within the
region deleted in our family.
Figure 2 Overview of H19/IGF2 genomic region on 11p15.5 including deletions and putative enhancer elements. Identification of candidate
IGF2 enhancer regions through the integration of data of chromatin features and sequence conservation at 11p15.5. The image shows an UCSC
Genome Browser screen shot including the most relevant information used to locate the putative enhancers. Two custom tracks have been
added: the copy number variations track showing the extension of the 100 kb deletion described in the paper and the 137 kb deletion described
by Baskin et al., 2014 (red bars); the putative enhancers of IGF2 showing four candidate regions represented by green boxes. Note that these regions
correspond to evolutionary conserved intronic regions that are enriched in H3K27Ac, H3K4me1, DNase hypersensitive sites and transcription factors
binding as reported by ENCODE (http://genome.ucsc.edu Chr11: 1,895,000-2,195,000; GRCh37/hg19 Feb 2009 assembly).
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methylation was included in the MS-MLPA kit, we per-
formed next generation bisulfite sequencing of the DMR0
of IGF2 in blood DNA from the mother, the father and
the son and an unrelated normal control. Normally this
DMR0 is hypermethylated (~70%) on the active paternal
allele of IGF2 and hypomethylated (~30%) on the silent
maternal allele [31] (and own unpublished data). We
found a hypermethylation of the DMR0 in the mother and
her son compared to the healthy father and the normal
control. For the six CpG dinucleotides studied, the mother
showed an average methylation of 71.7% and her son an
average methylation of 70.8%, while the average methyla-
tion in the father and the normal control (NC15) was
48.2% and 48.9%, respectively (see Figure 3B). Since the
patient and one of the normal controls were found to be
heterozygous for a single nucleotide polymorphism (SNP,
rs3741210, A > G) we were able to separate the parental
alleles. Since the mother of the patient is homozygous
for the G allele and the father is homozygous for the A
allele, the parental origin of the two alleles in the patient
could be determined. By this we could show that the
normal control has one allele which is hypermethylated
(72.5%) whereas the other allele is hypomethylated
(26.5%, see Figure 3C). In contrast, in the patient both
alleles (A and G) show a hypermethylation of 80.6% for
the paternal allele (A) and 62.7% for the maternal allele
(G), indicating that the maternal deletion allele acquired
methylation at the DMR0 although the deletion does
not overlap IGF2.
Our findings are in agreement with the results pub-
lished by Murrell et al. [31].Conclusions
BWS results from deregulation of imprinted genes on
chromosome 11p15 and is known to have clinical variabil-
ity and molecular heterogeneity. There are phenotypic
differences between the various molecular subgroups of
BWS [9]. Familial or de novo deletions affecting one of the
two ICRs in 11p15 are a rare cause of BWS. Only 14 dele-
tions for ICR1 have been described so far [14-21,23]. Ten
of these deletions are very small and affect only the ICR1
itself. These deletions affect multiple target sites (CTSs)
for the zinc-finger protein CTCF, whose binding on the
maternal allele blocks the access of the IGF2 promoter to
its downstream enhancers and enables H19 to use these
enhancers for transcription. The ICR1-DMR deletions
affect the ICR1 function and CTCF binding to different
extents resulting in variable expression of the clinical
phenotype depending on the spatial arrangement of the
remaining CTSs [21]. Of the four larger deletions result-
ing in BWS after maternal transmission reported by
Baskin et al. [19] three (18-25 kb) include the H19 gene
in addition to the ICR1 and one deletion of 137 kb in-
clude the non-imprinted genes MRPL23, its antisense
MRPL23-AS1, TNNT3 and part of the LSP1 gene down-
stream of H19. However, none of these deletions include
IGF2. The deletion in our family is ~100 kb in size and
includes H19, the miR-675, which is located inside H19,
the non-imprinted gene MRPL23, its antisense tran-
script MRPL23-AS1 and two of three putative enhancer
elements downstream of H19.
MRPL23 has previously been shown to be function-
ally insulated from the IGF2/ICR1/H19 domain in
terms of both imprinting and enhancer action [32].
Figure 3 Comparative methylation plots and heatmaps for the IGF2 DMR0. (A) Schematic view of the IGF2 DMR0 and the location of the
amplicon used for deep bisulfite sequencing (black bar; not drawn to scale). The exact position for the amplicon is chr11:2169292-2169605
(hg19, UCSC Browser). (B) The average methylation of the IGF2 DMR0 in the patient, his parents and a normal control. Compared to the father and
the normal control (NC) the mother and the patient show a hypermethylation for the IGF2 DMR0. (C) The average methylation of the separated
alleles (SNP rs3741210) in a normal control and the patient. One allele of the normal control is hypermethylated (indicating that it represents
the paternal allele), whereas the other allele is hypomethylated (indicating that it representing the maternal allele). In the patient the paternal
allele (A) is hypermethylated and the maternal allele (G), which should be hypomethylated, is hypermethylated as well. Each square represents
a CpG dinucleotide with its average methylation level, each line a specific sample. The average methylation over the analyzed region is given in
percentage on the left under the sample ID together with the number of analyzed reads in brackets. The methylation was analyzed over 6 CpGs.
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give rise to any of the BWS phenotypic features present
in the patient and the mother.
From mouse models but also from the deletion cases
with small deletions inside the ICR1-DMR it is knownthat maternal transmission of a ICR1-DMR deletion it-
self leads to reactivation of the maternal IGF2 copy and
therefore leads to biallelic expression of IGF2 resulting
in BWS [14,20,29] Reactivation of IGF2 is associated
with hypermethylation of the maternal allele [31]. We
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methylation of the maternal allele at the DMR0 of IGF2
in both, the patient and his mother. The DMR0 is lo-
cated 5′ to the main promoters of IGF2. In 2008 Murrell
and coworkers demonstrated that the IGF2-DMR0 is
subjected to different methylation changes in cancer and
congenital growth disorders [31]. In normal peripheral
blood and kidney the DMR0 is predominantly methyl-
ated on the paternal allele and unmethylated on the ma-
ternal allele. In addition, BWS patients with and without
microdeletions have IGF2-DMR0 as well as ICR1 hyper-
methylated while patients with Silver-Russell syndrome
(SRS), a growth retardation syndrome, have hypomethy-
lation at both of these sequences [31,33]. From these
data it has been concluded that in early embryonic de-
velopment the IGF2-DMR0 is methylated or unmethy-
lated according to the germline methylation imprint of
the ICR1-DMR. Gain of methylation of the DMR0 leads
to activation of the maternal IGF2 allele in ICR1 hyper-
methylated BWS cases and loss of methylation of the
DMR0 leads to silencing of the paternal IGF2 allele in
ICR1 hypomethylated SRS cases [31].
In the family presented here, the deletion patient and
his mother showed hypermethylation on the maternal
deletion allele at the IGF2 DMR0, indicating that the ma-
ternal allele is transcriptionally active. In this case, the
hypermethylation does not reflect the methylation status
of the ICR1-DMR since this DMR is deleted. However, it
may reflect the active state of the IGF2 promoters and
possibly arises as a consequence of the interaction of the
IGF2 promoters to its downstream enhancers. The exact
location of these downstream enhancers is well known in
mice but largely unknown in human [29]. By in silico ana-
lysis we could identify four candidate regions for putative
enhancers. Two of these sequences are affected by the
deletion in our family. From the methylation status of
IGF2 it seems that the residual two enhancer elements are
sufficient to drive IGF2 expression on the maternal allele.
Moreover, evidence that only the most telomeric and/or
the most centromeric putative enhancer elements are
needed to activate IGF2 comes from a patient with the
only similar deletion of 137 kb in size reported by Baskin
and colleagues [19]. Compared to our deletion, this dele-
tion includes one additional putative enhancer element
downstream of H19 (see Figure 2). Although methylation
or expression studies for IGF2 have not been performed
in this patient, there must be an activation of the maternal
IGF2 allele since the patient has phenotypic features of
BWS. However, Gronskov et al. [23] recently reported an
atypical SRS patient with a deletion in mosaic on the pa-
ternal chromosome 11, which is similar to the deletion in
our patient. The telomeric breakpoint of this deletion is
nearly the same whereas the centromeric breakpoint is
closer to H19 and therefore spans also the same enhancerelements as the deletion in our patient. It is interesting
that a deletion of H19 and its enhancers, in opposite in-
heritance, can give rise to either atypical SRS or BWS.
Furthermore, Gronskov et al. could show that in the SRS
patient methylation of the IGF2 DMR0 is slightly changed
to hypomethylation. The fact that aberrant methylation in
this patient is not very strong may be due to the mosaic
state of the deletion in this patient.
It is known that IGF2 has a key role in fetal and pla-
cental development by activating intracellular signaling
cascades that promote cell growth and survival.
Interestingly, in a recent study it has been reported
that the methylation level of IGF2DMR0 but not DMR2
is significantly increased in brain tissues of neural tube
defect fetuses and that a hypermethylation of the IGF2-
DMR0 is positively associated with an increased risk of
neural tube defects [34]. This might explain the presence
of spina bifida in the lower back of our deletion patient,
a feature which is not listed in the clinical features of
BWS [34]. However, alterations affecting the ICR1-DMR
and therefore in turn affecting IGF2 methylation and ex-
pression are only found in a minority of patients with
BWS (~10%), making a judgment of increased spina bifida
occurrence difficult. IGF2 upregulation is also known to
be associated with an increased risk for embryonal tumors
including Wilms tumor. Thus, the occurrence of embry-
onal tumors in early life is a major concern in patients
with BWS and ICR1/IGF2 alterations. Our patient has not
yet developed Wilms tumor but since he is at high risk for
tumor development ultrasound surveillance is being per-
formed in 3 month intervals until the age of 6 years.
Although the patient and his mother have the same
deletion, the clinical phenotype of the patient is more se-
vere than that of his mother. For example, he was se-
verely affected by hyperinsulinaemic hypoglycemia
which was not noted in his mother. A multidisciplinary
approach was necessary to prevent the threat on the pa-
tient’s life. It is not known how severely the patient with
the 137 kb deletion [19] was affected, since clinical data
for this patient have not been reported.
An increased clinical severity can be a random result
of variable phenotypic expression, which is not uncom-
mon in BWS. Evidence for anticipation in BWS in
members of a family with a maternally inherited OCT4
binding site mutation has recently reported by Berland
et al. [24]. Two sisters and their cousin had classical
BWS with Wilms tumor whereas their mothers and a
third sister of the mothers have only tall stature and only
one of these sisters showed also mild BWS features as a
child. In this family the increased clinical severity from
one generation to the next correlates with increased
methylation of the maternal ICR1-DMR. However, all
these individuals represent methylation mosaics with a
gain of methylation on their maternal chromosome. Since
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deleted an increased clinical severity could not be linked
to methylation differences of this DMR on the maternal
chromosome. In contrast, the hypermethylation of the
IGF2-DMR0 is similar in the patient and his mother and
could not explain the variable clinical expression. How-
ever, this does not exclude differences in methylation in
tissues other than blood.
We report here a novel familial deletion encompass-
ing most of the imprinted ICR1 region on chromosome
11p15. Both deletion carriers, the mother and the son,
have BWS with variable clinical expression, but similar
hypermethylation at IGF2 DMR0 in peripheral blood.
In silico analysis revealed that two of three putative en-
hancer elements downstream of H19 are affected by the
deletion, suggesting that the remaining two enhancers
are sufficient to drive IGF2 expression on the maternal
chromosome.Consent
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